Sign Out
There is limited experience of overdose with alpelisib (Pivikto) in clinical studies. In the clinical studies, alpelisib (Pivikto) was administered at doses up to 450 mg once daily.
In cases where accidental overdosage of alpelisib (Pivikto) was reported in the clinical studies, the adverse events associated with the overdose were consistent with the known safety profile of alpelisib (Pivikto) and included hyperglycemia, nausea, asthenia and rash.
General symptomatic and supportive measures should be initiated in all cases of overdosage where necessary. There is no known antidote for alpelisib (Pivikto).
